New hope for kidney cancer: experimental combo targets resistant tumors
NCT ID NCT06730932
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 31 times
Summary
This study tests a new drug (JS004) combined with toripalimab in 31 adults with advanced kidney cancer that got worse after prior immunotherapy. The goal is to see if the combination can shrink tumors or stop them from growing. Participants receive treatment for up to 2 years, and the study monitors side effects and disease progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE OR ADVANCED CLEAR CELL RENAL CELL CARCINOMA THAT HAS PROGRESSED AFTER PREVIOUS IMMUNOTHERAPY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200127, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.